Forest Lexapro “Not Approvable” For Panic Disorder Again
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA issues second “not approvable” letter for the selective serotonin reuptake inhibitor. Forest is reviewing FDA’s response and has not yet determined the appropriate next step.
You may also be interested in...
Forest Expects Lexapro To Gain Share In Flat Antidepressant Market
The company projects escitalopram total Rx share will increase from 19.7% to 21.5% in the next 12 months while the antidepressant market will be down 0.5% for the same period. Lexapro market share has seen a "modest boost" as a result of FDA's seizure of GSK's Paxil CR.
Forest Expects Lexapro To Gain Share In Flat Antidepressant Market
The company projects escitalopram total Rx share will increase from 19.7% to 21.5% in the next 12 months while the antidepressant market will be down 0.5% for the same period. Lexapro market share has seen a "modest boost" as a result of FDA's seizure of GSK's Paxil CR.
Forest Lexapro “Not Approvable” For Social Anxiety Disorder
FDA’s concerns regarded reliability of data from one of the pivotal studies, Forest says – an additional study may be necessary. Forest announced Lexapro was deemed “not approvable” for panic disorder March 1.